← Back to Treatments
🏅 FDA Orphan Designation

Zevaskyn

PRADEMAGENE ZAMIKERACEL

Manufacturer: Abeona Therapeutics Inc.

Indicated for:
Dystrophic epidermolysis bullosaOrphan

FDA-Approved Indications (1)

treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB)

Indications & Usage

1 INDICATIONS AND USAGE ZEVASKYN is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ( 1 )

💙 Support Programs

View all →
Zevaskyn
Abeona Therapeutics Inc.
ZEVASKYN
Unknown

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.